Hecht, Markus and Hahn, Dennis and Wolber, Philipp and Hautmann, Matthias G. and Reichert, Dietmar and Weniger, Steffi and Belka, Claus and Bergmann, Tobias and Goehler, Thomas and Welslau, Manfred and Grosse-Thie, Christina and Guntinas-Lichius, Orlando and von der Gruen, Jens and Balermpas, Panagiotis and Orlowski, Katrin and Messinger, Diethelm and Stenzel, Karsten G. and Fietkau, Rainer (2020) Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer. BMC CANCER, 20 (1): 933. ISSN , 1471-2407
Full text not available from this repository. (Request a copy)Abstract
BackgroundHead and neck squamous cell cancer (HNSCC) frequently causes severe symptoms that may be reduced, when the tumor is successfully treated. The SOCCER trial studied the association of treatment response with patient reported tumor symptom burden in first line treatment of recurrent and/or metastatic HNSCC.MethodsIn this prospective, multi-center, non-interventional trial patients were treated either with platinum-based chemotherapy and cetuximab or radiotherapy and cetuximab. Tumor symptom burden was assessed every four weeks with a questionnaire containing ten visual analogue scales (VAS, range 0-100), which were summarized to the overall VAS score.ResultsFourhundred seventy patients were registered in 97 German centers. A total of 315 patients with at least the baseline and one subsequent questionnaire were available for analysis. Changes in the VAS score were rated as absolute differences from baseline. Negative values indicate improvement of symptoms. The overall VAS score improved significantly at the first post-baseline assessment in responders (-2.13 vs. non-responders +1.15, p=0.048), and even more for the best post-baseline assessment (-7.82 vs. non-responders -1.97, p=0.0005). The VAS for pain (-16.37 vs. non-responders -8.89, p=0.001) and swallowing of solid food (-16.67 vs. non-responders -5.06, p=0.002) improved significantly more in responders (best post-baseline assessment). In the multivariable Cox regression analysis, worse overall VAS scores were associated with worse overall survival (hazard ratio for death 1.12 per 10 points increment on the overall VAS scale, 95% CI 1.05-1.20, p=0.0009).ConclusionIn unselected patients beyond randomized controlled trials, treatment response lowers tumor symptom burden in recurrent and/or metastatic HNSCC.Trial registrationClinicalTrials.gov, NCT00122460. Registered 22 Juli 2005,
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | SQUAMOUS-CELL CARCINOMA; CHEMOTHERAPY PLUS CETUXIMAB; Symptom; Response; HNSCC; Cetuximab; Chemotherapy |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Strahlentherapie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 10 Mar 2021 13:31 |
| Last Modified: | 10 Mar 2021 13:31 |
| URI: | https://pred.uni-regensburg.de/id/eprint/43739 |
Actions (login required)
 |
View Item |
